• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?

作者信息

Goense Lucas, van Hillegersberg Richard

机构信息

Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.

出版信息

Ann Surg Oncol. 2024 Jun;31(6):3567-3568. doi: 10.1245/s10434-024-15158-3. Epub 2024 Mar 8.

DOI:10.1245/s10434-024-15158-3
PMID:38457101
Abstract
摘要

相似文献

1
Adjuvant Nivolumab in Esophageal Cancer with Positive Resection Margins: A Premature Leap?食管癌切缘阳性患者的辅助性纳武单抗治疗：操之过急？
Ann Surg Oncol. 2024 Jun;31(6):3567-3568. doi: 10.1245/s10434-024-15158-3. Epub 2024 Mar 8.
2
[New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].[新的美国医学杂志文章：纳武单抗用于一线化疗后的晚期食管鳞状细胞癌]
Bull Cancer. 2021 Mar;108(3):228-229. doi: 10.1016/j.bulcan.2020.12.005. Epub 2021 Jan 30.
3
Short-term Outcomes of Adjuvant Nivolumab After Neoadjuvant Chemotherapy in Patients With Resected Esophageal Squamous Cell Carcinoma.新辅助化疗后辅助纳武利尤单抗治疗切除的食管鳞癌患者的短期结局。
Anticancer Res. 2024 Jan;44(1):185-193. doi: 10.21873/anticanres.16801.
4
The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.手术后继发围手术期化疗在食管或胃食管交界处腺癌患者中的作用：一项多中心队列研究。
J Gastrointest Surg. 2019 Sep;23(9):1729-1741. doi: 10.1007/s11605-018-04087-8. Epub 2019 Jan 22.
5
Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).一项评估纳武利尤单抗作为术前多西他赛、顺铂加氟尿嘧啶治疗（PENTAGON 试验）后食管癌患者术后辅助治疗的疗效和安全性的 II 期研究方案。
PLoS One. 2024 Apr 18;19(4):e0299742. doi: 10.1371/journal.pone.0299742. eCollection 2024.
6
ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.ASO作者反思：胸段食管鳞状细胞癌患者食管切除术后的预后分层及辅助治疗的价值
Ann Surg Oncol. 2019 Dec;26(Suppl 3):802-803. doi: 10.1245/s10434-019-07728-7. Epub 2019 Oct 25.
7
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.纳武利尤单抗治疗日本食管癌患者的长期疗效和应答预测因素分析。
Cancer Sci. 2020 May;111(5):1676-1684. doi: 10.1111/cas.14380. Epub 2020 Apr 29.
8
Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.纳武利尤单抗二线治疗晚期食管鳞癌的成本效果分析。
Future Oncol. 2020 Jun;16(17):1189-1198. doi: 10.2217/fon-2019-0821. Epub 2020 May 14.
9
[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].[欧洲药品管理局（EMA）新批准的药物：纳武利尤单抗联合化疗作为一线治疗用于治疗PD-L1表达（综合阳性评分[CPS]≥5）的HER2阴性食管腺癌]
Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.
10
[A Case of Long-Term Survival by Multidisciplinary Surgical Treatment for Metastatic Multi-Organ Metastasis after Radical Resection of Esophageal Cancer].[1例食管癌根治术后多器官转移行多学科手术治疗长期生存病例]
Gan To Kagaku Ryoho. 2022 Dec;49(13):1992-1994.

本文引用的文献

1
Adjuvant Therapy for Patients with a Tumor-Positive Resection Margin After Neoadjuvant Chemoradiotherapy and Esophagectomy.新辅助放化疗和食管切除术后肿瘤阳性切缘患者的辅助治疗。
Ann Surg Oncol. 2024 Jun;31(6):3813-3818. doi: 10.1245/s10434-024-14912-x. Epub 2024 Jan 20.
2
Adjuvant Therapy After Neoadjuvant Therapy for Esophageal Cancer: Who Needs It?新辅助治疗后食管癌的辅助治疗：谁需要？
Ann Surg. 2023 Aug 1;278(2):e240-e249. doi: 10.1097/SLA.0000000000005679. Epub 2022 Aug 23.
3
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3).
纳武利尤单抗治疗既往治疗的晚期食管鳞癌患者的 3 年随访和应答生存关系（ATTRACTION-3）。
Clin Cancer Res. 2022 Aug 2;28(15):3277-3286. doi: 10.1158/1078-0432.CCR-21-0985.
4
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.纳武利尤单抗辅助治疗食管或胃食管结合部癌。
N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125.
5
Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.腺癌患者食管切除术后切缘阳性的辅助治疗。
Br J Surg. 2020 Dec;107(13):1801-1810. doi: 10.1002/bjs.11864. Epub 2020 Sep 29.
6
The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis.辅助治疗在切缘阳性（R1）食管癌患者中的作用：一项全国性分析。
J Surg Res. 2020 May;249:82-90. doi: 10.1016/j.jss.2019.11.035. Epub 2020 Jan 8.